These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29398693)

  • 1. Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma.
    Aoyama T; Imataki O; Arai H; Kume T; Shiozaki H; Katsumata N; Mori M; Ishide K; Ikeda T
    Med Sci Monit Basic Res; 2018 Feb; 24():31-39. PubMed ID: 29398693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
    Zhou P; Liu P; Zhou SY; He XH; Han XH; Qin Y; Yang S; Zhang CG; Gui L; Yao JR; Zhao LY; Zhang SX; Sun Y; Shi YK
    Chin Med J (Engl); 2015 Sep; 128(18):2498-504. PubMed ID: 26365969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.
    Fox CP; McMillan AK; Bishton MJ; Haynes AP; Russell NH
    Br J Haematol; 2008 Apr; 141(2):244-8. PubMed ID: 18353164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
    Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.
    Kameoka Y; Takahashi N; Ishizawa K; Kato Y; Ito J; Sasaki O; Murai K; Noji H; Hirokawa M; Tajima K; Shichishima T; Ishida Y; Harigae H; Sawada K
    Int J Hematol; 2012 Nov; 96(5):624-30. PubMed ID: 23054649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma.
    Kobayashi Y; Hatta Y; Sugitani M; Hojo A; Nakagawa M; Kusuda M; Uchino Y; Takahashi H; Kiso S; Hirabayashi Y; Yagi M; Kodaira H; Kurita D; Miura K; Iriyama N; Kobayashi S; Kura Y; Horikoshi A; Sawada U; Takeuchi J; Takei M
    Leuk Lymphoma; 2014 Nov; 55(11):2514-9. PubMed ID: 24491027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute renal toxicity of 2 conditioning regimens in patients undergoing autologous peripheral blood stem-cell transplantation. Total body irradiation-cyclophosphamide versus ifosfamide, carboplatin, etoposide.
    Beyzadeoglu M; Arpaci F; Surenkok S; Ozyigit G; Oysul K; Caglar K; Ataergin S; Yenicesu M; Kaya A
    Saudi Med J; 2008 Jun; 29(6):832-6. PubMed ID: 18521460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
    Imataki O; Aoyama T; Tamai Y; Kawakami K
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose carboplatin, etoposide and ifosfamide and autologous stem cell rescue in the treatment of non-Hodgkin lymphoma.
    Siegert W
    Pathol Biol (Paris); 1993 Jan; 41(1):104. PubMed ID: 8316443
    [No Abstract]   [Full Text] [Related]  

  • 20. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.